Akari Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Akari Therapeutics PLC
AKTX Stock  USD 0.25  0.01  4.17%   
Akari Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Akari Therapeutics' valuation are provided below:
Market Capitalization
17 M
We have found one hundred twenty available fundamental signals for Akari Therapeutics PLC, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Akari Therapeutics PLC prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Enterprise Value is likely to rise to about 638.4 K in 2026, whereas Market Cap is likely to drop slightly above 15.9 K in 2026.
Check Akari Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akari Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 266.6 K, Selling General Administrative of 7.8 M or Other Operating Expenses of 17.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 8.0E-4. Akari financial statements analysis is a perfect complement when working with Akari Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Akari Stock
Check out the analysis of Akari Therapeutics Correlation against competitors.

Akari Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets61.1 M58.1 M23.6 M
Slightly volatile
Other Current Liabilities5.2 M4.9 M4.7 M
Pretty Stable
Total Current Liabilities24 M22.9 M9.1 M
Slightly volatile
Accounts Payable15 M14.3 M3.9 M
Slightly volatile
Cash And Short Term Investments2.2 M2.3 M12.7 M
Pretty Stable
Net Receivables219.6 K231.2 K2.7 M
Very volatile
Common Stock Shares Outstanding13 K13.7 K736.9 K
Very volatile
Liabilities And Stockholders Equity61.1 M58.1 M23.6 M
Slightly volatile
Other Current Assets166.1 K174.8 K590.6 K
Pretty Stable
Other Stockholder Equity319.9 M304.6 M127.2 M
Slightly volatile
Total Liabilities34.2 M32.6 M11 M
Slightly volatile
Total Current Assets3.2 M3.4 M14.1 M
Pretty Stable
Common Stock9.2 M6.1 M8.3 M
Very volatile
Cash2.2 M2.3 M12.1 M
Pretty Stable
Common Stock Total Equity420.3 K442.4 K7.1 M
Very volatile
Short and Long Term Debt Total3.9 M3.7 M2.5 M
Slightly volatile
Non Current Assets Total57.5 M54.8 M9.5 M
Slightly volatile
Property Plant And Equipment Gross207.7 K197.8 K91.1 K
Slightly volatile
Short Term Debt3.9 M3.7 M2.5 M
Slightly volatile
Short and Long Term Debt3.9 M3.7 M2.6 M
Slightly volatile
Intangible Assets47.3 M45.1 M7.8 M
Slightly volatile
Other Liabilities55.7 K55.2 K49.7 K
Pretty Stable
Non Current Liabilities Other462.5 K440.4 K236.8 K
Slightly volatile
Capital Surpluse119.4 M127.1 M109.9 M
Slightly volatile
Capital Stock7.3 M4.8 M15.6 M
Slightly volatile

Akari Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative7.8 M11.1 M7.4 M
Slightly volatile
Other Operating Expenses17.4 M24.9 M16.5 M
Slightly volatile
Research Development9.8 M8 M9 M
Slightly volatile
Total Operating Expenses17.4 M24.9 M16.5 M
Slightly volatile
Interest Income6.8 K7.2 K3 M
Slightly volatile
Reconciled Depreciation13.2 K12.6 K26.8 K
Slightly volatile
Selling And Marketing Expenses9.1 M10.2 M11.1 M
Slightly volatile

Akari Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow4.2 M4.4 M12 M
Very volatile
Total Cash From Financing Activities16.2 M12.6 M14.7 M
Pretty Stable
End Period Cash Flow2.3 M2.4 M12.1 M
Pretty Stable
Stock Based Compensation1.3 M2.6 M1.2 M
Slightly volatile
Depreciation12.2 K12.6 K13.3 K
Pretty Stable
Sale Purchase Of Stock16.9 M11.4 M13.7 M
Very volatile
Issuance Of Capital Stock15.1 M13.6 M7.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Invested Capital6.4 M5.9 M5.6 M
Slightly volatile
Average Payables2.1 M1.6 M2.1 M
Slightly volatile
Capex To Depreciation0.951.02.7614
Slightly volatile
Payables Turnover0.01280.01410.0116
Slightly volatile
Cash Per Share23825023.2 K
Slightly volatile
Days Payables Outstanding51 K26.9 K70.8 K
Slightly volatile
Income Quality0.730.570.8795
Pretty Stable
Tangible Asset Value5.9 M5.6 M5.2 M
Slightly volatile
Intangibles To Total Assets0.890.850.1587
Slightly volatile
Current Ratio0.160.172.1351
Slightly volatile
Capex Per Share10968.0284.5496
Pretty Stable
Average Receivables3.3 K3.5 K5.3 K
Slightly volatile
Interest Debt Per Share2162273.4 K
Slightly volatile
Debt To Assets0.07040.07410.1879
Slightly volatile
Days Of Payables Outstanding51 K26.9 K70.8 K
Slightly volatile
Ebt Per Ebit1.01.050.9223
Very volatile
Quick Ratio0.160.172.1847
Slightly volatile
Net Income Per E B T0.880.780.7912
Slightly volatile
Cash Ratio0.140.151.762
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9835
Slightly volatile
Debt Ratio0.07040.07410.1879
Slightly volatile

Akari Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap15.9 K16.8 K43.9 K
Slightly volatile

Akari Fundamental Market Drivers

Akari Upcoming Events

6th of May 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Akari Therapeutics Financial Statements

Akari Therapeutics investors use historical fundamental indicators, such as Akari Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Akari Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue(480.24)(504.25)
Cost Of Revenue12.6 K9.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY